Navigation Links
Study Confirms Effectiveness of Innovative Prism Glasses For Hemianopia Patients
Date:5/19/2009

Suggests additional training to help brain adapt more fully and further enhance benefits

BOSTON, May 19 /PRNewswire-USNewswire/ -- In a study of specially designed peripheral prism glasses for hemianopia patients (blinded in half the visual field in both eyes), scientists found that two-thirds of patients continued to wear the glasses at the end of the study period and beyond, indicating a high level of success. They also found that the brains of patients had not fully remapped to adjust for the prisms, which means that improved training in their use could further enhance the benefits, says principal investigator, Dr. Eli Peli, a senior scientist at Schepens Eye Research Institute and inventor of the glasses.

The study, published in the May 2009 issue of Optometry and Vision Science, not only reaffirms previous clinical studies, but also adds a deeper understanding of the neurological processes at play when a patient uses prisms for this purpose, adds Peli.

More than a million Americans suffer from hemianopia, which blinds the vision in one half of the visual field in both eyes -- the result of strokes, tumors or trauma. Hemianopia patients are often unaware of what they cannot see and frequently bump into walls, trip over objects or walk into people on the side where the visual field is missing.

The prisms, attached above and below the center of a spectacle lens in Peli's invention, shift images from one side of the visual field to the other side and alert patients to objects and obstacles not otherwise visible to them. Alerted to the existence of these objects, patients turn to look, or, if their brains are fully adapted (remapped), perceive quickly where the objects are and automatically avoid them without turning their eyes and head. (In earlier designs by other scientists, the prism was in the middle of the lens and caused double vision.)

"The best case scenario," says Peli, "is for a patient to be able to make rapid decisions based on the perception rather than moving their heads when an unseen object is detected."

Peli and his team asked 28 patients with complete hemianopia to wear the peripheral prism glasses as much as possible for the duration of the study, which averaged about nine weeks. Success was measured by continued wear, visual field expansion, perceived direction (caused by brain remapping), and perceived improvement in quality of life.

The research team found that 67 percent of patients chose to continue to wear the glasses at the end of the study. They also found that all patients had expansion of their visual field of about 22 degrees and expressed reduced difficulty in noticing and avoiding obstacles. On the other hand, only two patients demonstrated even an intermittent adaptation to the change in visual direction produced by the peripheral prism glasses, which means that no patient had remapped his or her brain to automatically make the perceptual adjustment.

Based on these results, Dr. Peli and his team plan to conduct future research that will examine the best way to train patients to reprogram their brains to perceive direction automatically.

The research team consisted of Mr. Robert Giorgi and Drs. Russell Woods and Eli Peli, all of the Schepens Eye Research Institute.

This study was conducted with a prototype of the glasses, on which the prisms are temporarily applied. There are now permanent prism glasses available, which continue to be studied and perfected in on-going multi-center trials.

Patients interested in trying the peripheral prism glasses can contact Chadwick Optical for referral to a doctor in their area. Go to http://www.chadwickoptical.com/ for contact information.

Schepens Eye Research Institute is an affiliate of Harvard Medical School and the largest independent eye research institute in the nation.


'/>"/>
SOURCE Schepens Eye Research Institute
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/9/2017)... , May 9, 2017  Oramed Pharmaceuticals Inc. ... a clinical-stage pharmaceutical company focused on the development ... the Canadian Intellectual Property Office has granted Oramed ... Administration of Exenatide". The patent covers Oramed,s invention ... GLP-1 is an incretin hormone that stimulates ...
(Date:5/6/2017)... Provista , a proven leader in the supply chain industry ... Jim Cunniff as the company,s new president and CEO. ... Provista, including most recently serving as the president and CEO ... He assumed his new role with Provista on May 1, ... says Jody Hatcher , president, Sourcing and Collaboration Services ...
(Date:5/4/2017)... MEMPHIS, Tenn. , May 4, 2017 /PRNewswire/ ... of Infection Control, Ultraviolet-C light as ... demonstrated Tru-D SmartUVC,s ability to reduce bioburden on ... influenced bioburden reduction on high-touch, complex medical equipment ... in surgical infections. "This study further ...
Breaking Medicine Technology:
(Date:5/24/2017)... ... 2017 , ... The CFOs included on this list lead ... the nation and help their organizations navigate the challenges in healthcare today. These ... developing successful hospital and health system strategy. , Becker's Hospital Review has published ...
(Date:5/24/2017)... (PRWEB) , ... May 24, 2017 , ... Technique, technique, ... back injury when either lifting weights for strength training and exercise or simply lifting ... Center . , “Body position is everything,” Dr. Chang says. “Improper technique in lifting ...
(Date:5/23/2017)... ... May 23, 2017 , ... MDLand ... Integration company, announced today that its iClinic V12.2 solution has achieved approval from ... NCQA recently introduced PCMH 2017 standards which emphasize team-based care with a significant ...
(Date:5/23/2017)... ... ... Allegheny Health Network and the Alexis Joy D’Achille Foundation ... at West Penn Hospital , a unique facility that will offer the most ... Construction of the Center is underway with a scheduled opening in the fall of ...
(Date:5/23/2017)... ... May 23, 2017 , ... Cambridge, MA, May 23, 2017—Total ... according to a Workers Compensation Research Institute (WCRI) study, a contrast from the ... System: CompScope™ Benchmarks, 17th Edition looks at indemnity and medical payments for ...
Breaking Medicine News(10 mins):